Affiliation: Bristol-Myers Squibb
- RNAi versus small molecules: different mechanisms and specificities can lead to different outcomesKevin Fitzgerald
Bristol Myers Squibb Co, Department of Applied Genomics, Pharmaceutical Research Institute, P O Box 5400, Princeton, NJ 08534, USA
Curr Opin Drug Discov Devel 8:557-66. 2005..This review discusses the similarities, as well as the predicted differences between RNAi and small molecule effects on therapeutic paradigms and drug discovery...
- Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitorsMark R Lackner
Exelixis Inc, 170 Harbor Way, South San Francisco, California 94083, USA
Cancer Cell 7:325-36. 2005..These findings validate RabGGT, and by extension endosomal function, as a therapeutically relevant target for modulation of apoptosis, and enhance our understanding of the mechanism of action of FTIs...
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesMaria Frank-Kamenetsky
Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA
Proc Natl Acad Sci U S A 105:11915-20. 2008..These results validate PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia...